Segura E, Ayoub P, Hart K, Kohn D
Viruses. 2023; 15(3).
PMID: 36992422
PMC: 10054523.
DOI: 10.3390/v15030713.
Wu X, He X, Liu F, Jiang X, Wang P, Zhang J
Comput Struct Biotechnol J. 2022; 20:2986-3003.
PMID: 35782737
PMC: 9218169.
DOI: 10.1016/j.csbj.2022.06.015.
Quintana-Bustamante O, Fananas-Baquero S, Dessy-Rodriguez M, Ojeda-Perez I, Segovia J
Front Physiol. 2022; 13:848261.
PMID: 35418876
PMC: 8995967.
DOI: 10.3389/fphys.2022.848261.
Rosanwo T, Bauer D
Mol Ther. 2021; 29(11):3163-3178.
PMID: 34628053
PMC: 8571174.
DOI: 10.1016/j.ymthe.2021.10.002.
Karamperis K, Tsoumpeli M, Kounelis F, Koromina M, Mitropoulou C, Moutinho C
Hum Genomics. 2021; 15(1):32.
PMID: 34090531
PMC: 8178887.
DOI: 10.1186/s40246-021-00329-0.
Enhanced Transduction of Human Hematopoietic Stem Cells by AAV6 Vectors: Implications in Gene Therapy and Genome Editing.
Yang H, Qing K, Keeler G, Yin L, Mietzsch M, Ling C
Mol Ther Nucleic Acids. 2020; 20:451-458.
PMID: 32276210
PMC: 7150427.
DOI: 10.1016/j.omtn.2020.03.009.
Mouse models in hematopoietic stem cell gene therapy and genome editing.
Radtke S, Humbert O, Kiem H
Biochem Pharmacol. 2019; 174:113692.
PMID: 31705854
PMC: 7050335.
DOI: 10.1016/j.bcp.2019.113692.
Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced.
Leonard A, Tisdale J
Expert Rev Hematol. 2018; 11(7):547-565.
PMID: 29883237
PMC: 8459571.
DOI: 10.1080/17474086.2018.1486703.
Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong A, Rivella S
Adv Exp Med Biol. 2017; 1013:155-176.
PMID: 29127680
PMC: 5718882.
DOI: 10.1007/978-1-4939-7299-9_6.
Gene therapy for hemoglobin disorders - a mini-review.
Rai P, Malik P
J Rare Dis Res Treat. 2016; 1(2):25-31.
PMID: 27891535
PMC: 5120727.
The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.
Goodman M, Malik P
Ther Adv Hematol. 2016; 7(5):302-315.
PMID: 27695619
PMC: 5026290.
DOI: 10.1177/2040620716653729.
Current and future alternative therapies for beta-thalassemia major.
de Dreuzy E, Bhukhai K, Leboulch P, Payen E
Biomed J. 2016; 39(1):24-38.
PMID: 27105596
PMC: 6138429.
DOI: 10.1016/j.bj.2015.10.001.
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O, Eggimann A, Beuzard Y, Ribeil J, Bourget P, Borwornpinyo S
Hum Gene Ther. 2016; 27(2):148-65.
PMID: 26886832
PMC: 4779296.
DOI: 10.1089/hum.2016.007.
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.
Hoban M, Orkin S, Bauer D
Blood. 2016; 127(7):839-48.
PMID: 26758916
PMC: 4760089.
DOI: 10.1182/blood-2015-09-618587.
A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.
Fusil F, Calattini S, Amirache F, Mancip J, Costa C, Robbins J
Mol Ther. 2015; 23(11):1734-1747.
PMID: 26281898
PMC: 4817946.
DOI: 10.1038/mt.2015.148.
Gene therapy for hemoglobinopathies: the state of the field and the future.
Chandrakasan S, Malik P
Hematol Oncol Clin North Am. 2014; 28(2):199-216.
PMID: 24589262
PMC: 4167426.
DOI: 10.1016/j.hoc.2013.12.003.
Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.
Larochelle A, Dunbar C
Semin Hematol. 2013; 50(2):101-30.
PMID: 24014892
PMC: 3761403.
DOI: 10.1053/j.seminhematol.2013.03.025.
Gene therapy for hemoglobinopathies: progress and challenges.
Dong A, Rivella S, Breda L
Transl Res. 2013; 161(4):293-306.
PMID: 23337292
PMC: 3716457.
DOI: 10.1016/j.trsl.2012.12.011.
Development of gene therapy for thalassemia.
Nienhuis A, Persons D
Cold Spring Harb Perspect Med. 2012; 2(11).
PMID: 23125203
PMC: 3543108.
DOI: 10.1101/cshperspect.a011833.
Recent advances in gene therapy for thalassemia.
Raja J, Rachchh M, Gokani R
J Pharm Bioallied Sci. 2012; 4(3):194-201.
PMID: 22923960
PMC: 3425167.
DOI: 10.4103/0975-7406.99020.